# Spectrumedics Medical

> Spectrumedics Medical is a Singapore-based medical device company building active, minimally-invasive cardiovascular interventional systems. Its flagship product, the Sonico-CX intravascular lithotripsy (IVL) system, uses acoustic pressure waves to break up calcified coronary lesions so cardiologists can restore blood flow and place stents. In January 2026 the company earned an EU CE mark, joining Johnson & Johnson MedTech's Shockwave and Elixir Medical as one of the few companies with EU-approved coronary IVL systems. Backed by a Series A round led by Legend Capital, Spectrumedics operates from the JTC MedTech Hub and is commercializing across Asia Pacific and Latin America while expanding into Europe and the Middle East.

- **Founded:** 2018
- **Headquarters:** Singapore
- **Founders:** Elynn Phang (Founder & CEO), Peng Huiqun (Co-Founder), Al Ray Tabiliran (Co-Founder)
- **Team size:** ~11 employees
- **Products:** Sonico-CX Coronary IVL System, Sonico-PX Peripheral IVL Platform, Intravascular Lithotripsy Generator
- **Notable:** Received EU CE mark under EU MDR for its Sonico-CX coronary IVL system in January 2026., Became one of only three companies worldwide with an EU-approved coronary intravascular lithotripsy system, alongside J&J's Shockwave and Elixir Medical., Raised a Series A round led by Legend Capital (reported at hundreds of millions of CNY).

## Products & services

- **Sonico-CX Coronary IVL System** — An intravascular lithotripsy system pairing the Sonico-CX coronary catheter with an IVL generator. It delivers 360-degree circumferential acoustic pressure waves (up to 120 pulses per catheter) to modify superficial and deep calcified coronary lesions, improving vessel compliance and facilitating stent implantation. Offered in seven balloon sizes from 2.5 to 4.0 mm with a low crossing profile.
- **Sonico-PX Peripheral IVL Platform** — An earlier intravascular lithotripsy platform using electrohydraulic lithotripsy emitters that convert electrical energy into shockwaves to break up calcium deposits in peripheral arteries while protecting surrounding vessel tissue. Entered peripheral trials in late 2021.
- **Intravascular Lithotripsy Generator** — The console that powers Sonico catheters, generating and controlling the acoustic pulse energy delivered during the procedure.

## Achievements

- Received EU CE mark under EU MDR for its Sonico-CX coronary IVL system in January 2026.
- Became one of only three companies worldwide with an EU-approved coronary intravascular lithotripsy system, alongside J&J's Shockwave and Elixir Medical.
- Raised a Series A round led by Legend Capital (reported at hundreds of millions of CNY).
- Achieved commercial clearances and rollouts across Asia Pacific and Latin America.
- Completed peripheral and coronary clinical studies of its Sonico IVL platform.

## Latest updates

- **2026-01** — Spectrumedics announced CE mark approval (EU MDR, via BSI) for its Sonico-CX coronary intravascular lithotripsy system, clearing the way for European commercialization.
- **2025-08** — Showcased the Sonico-CX IVL catheter and generator system publicly via LinkedIn, highlighting 360-degree energy delivery and up to 120 pulses per catheter.
- **2022-05** — Closed a Series A round led by Legend Capital to fund R&D, expand its shockwave catheter product line and scale manufacturing.

## Links

- Website: https://spectrumedics.com
- LinkedIn: https://sg.linkedin.com/company/spectrumedics
- Instagram: https://www.instagram.com/spectrumedics/
- Facebook: https://www.facebook.com/spectrumedics/

---

Profile page: https://yespress.io/spectrumedics-medical
Published by YesPress — https://yespress.io
Last updated: 2026-07-25